# Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS

> **NCT02048969** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- Hepatic Encephalopathy
- Liver Cirrhosis

## Interventions

- **DRUG:** Flumazenil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02048969
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-06
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects were able to be recruited for the study.
- **Last updated:** 2020-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02048969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02048969, "Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02048969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*